Clinical Trials Browser

Recruiting × INDUSTRY × elacestrant × Clear all

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1 Recruiting

399 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06492616 2026-05-27

ELEGANT

Phase 3 Recruiting

4,220 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06638307 2026-05-12

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Phase 1 Recruiting

240 enrolled

Breast

Advanced Breast Cancer

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

95 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT06544577 2024-08-09

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Recruiting

350 enrolled

Breast

ESR1 Gene Mutation

Clinical Trials

ELECTRA

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

ELEGANT

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

ELEVATE

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC